<DOC>
	<DOCNO>NCT01439009</DOCNO>
	<brief_summary>One tolvaptan 15 mg tablet placebo tablet orally administer daily morning 14 day heart failure patient volume overload show adequate response diuretic loop diuretic order investigate effect tolvaptan mid- long-term prognosis target population . The efficacy tolvaptan treatment period also investigate .</brief_summary>
	<brief_title>Effect Tolvaptan Mid- Long-term Prognosis Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients informed consent properly obtain write prior start trial Patients clinically diagnose heart failure Patients follow condition symptom : low limb edema , dyspnea , jugular venous distension , hepatomegaly , pulmonary rale , third heart sound , pulmonary congestion Patients receive loop diuretic , thiazide diuretic , antialdosterone diuretic Male female patient age 20 85 year inclusive ( time inform consent ) Patients , together partner ( ) , able use appropriate method contraception 3 month final trial drug administration Patients able hospitalize trial site least 7 day start trial drug administration Patients history hypersensitivity ingredient drug tolvaptan analogue ( e.g. , mozavaptan hydrochloride ) Patients anuria Patients sense thirst difficulty fluid intake Patients hypernatremia ( serum sodium concentration &gt; institutional upper limit normal ) 5 ) Female patient pregnant , possibly pregnant , nursing Patients judge investigator subinvestigator inappropriate inclusion trial due follow condition symptom : Hyponatremia ( serum sodium concentration &lt; 125 mEq/L ) Serious coronary artery disease cerebrovascular disease Hyperkalemia Severe renal disorder Poorly control diabetes mellitus Severe hepatic disease Impaired urinary excretion due urinary stenosis , calculus , tumor Cardiac valve disease significant heart valve stenosis Malignant tumor unfavorable prognosis Patients suspect hypovolemia Patients implant circulatory support device Patients acute cardiac infarction occur within 30 day prior screen examination Patients participate clinical trial postmarketing clinical trial within 30 day prior date informed consent present trial Patients receive tolvaptan within 26 week prior date informed consent Patients otherwise judge investigator subinvestigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Volume overload</keyword>
	<keyword>Tolvaptan</keyword>
	<keyword>loop diuretic</keyword>
</DOC>